Italian antitrust authority opens phase-two review of Intesa Sanpaolo's bid for Monte dei Paschi, spotlighting insurance operations as a key concern
Executive summary: The AGCM announced it will open phase two of its antitrust investigation into Intesa Sanpaolo’s Opas on Monte dei Paschi di Siena, with a particular focus on the insurance component of the offer. The outcome could impose conditions, require divestitures, or ultimately prohibit the merger, affecting the structure of Italy’s banking sector and the competitive dynamics of bancassurance.
Who is involved: Intesa Sanpaolo, Monte dei Paschi di Siena (Mps), the Italian Antitrust Authority (AGCM), and the insurance subsidiaries of both banks.
Likely next (inference): The AGCM will collect further information and may propose remedies; Intesa Sanpaolo may respond with concessions, while Mps could continue defending the deal via its Consob filing on related-party transactions.
The Autorità Garante della Concorrenza e del Mercato (AGCM) has notified Intesa Sanpaolo that it will advance to the second phase of its merger scrutiny, focusing on the insurance assets tied to the deal. This move follows months of warnings from Mps and other stakeholders about potential competition risks in the banking‑insurance sector. While the investigation does not yet block the offer, it raises the likelihood of remedies or a veto that could reshape Italy’s banking consolidation landscape.
What's next — scenarios
Inference: scenarios and probabilities are Beyond's assessment, not reported fact.
Conditional Approval with Structural Remedies (55%)
Intesa Sanpaolo is forced to divest specific insurance distribution channels or subsidiaries to preserve market competition.
- AGCM announcement of required asset divestitures
- Intesa Sanpaolo accepts specific behavioral remedies
Regulatory Veto/Blockage (25%)
The acquisition fails, leaving Monte dei Paschi as a standalone entity or forcing a search for a different buyer.
- AGCM issues a formal prohibition of the merger
- Failure to reach agreement on remedy packages
Unconditional Clearance (20%)
The deal proceeds as planned, accelerating Intesa Sanpaolo's dominance in the Italian bancassurance market.
- AGCM closes phase-two without imposing mandatory divestments
- Regulatory focus shifts away from insurance synergies
What to watch
- AGCM official press releases regarding the phase-two timeline (next 30-60 days)
- Intesa Sanpaolo investor relations communications on deal contingency plans
- Market pricing of MPS shares relative to merger premium volatility (next 90 days)
- Official statements from MPS management regarding competition concerns
Timeline
- — Opas Mps, via all’istruttoria Antitrust per Intesa Sanpaolo il nodo assicurazioni (la Repubblica — Economia)
Analysis — what this means
Sectors affected
- Banking
- Insurance
Regulatory implications
- AGCM merger control review under Italian competition law (Law 287/1990) and EU Treaty Articles 101‑102
- Possibility of a final prohibition decision if competitive concerns remain unresolved
Historical parallels
- Intesa Sanpaolo, l’offerta su Mps al test dell’Antitrust – la Repubblica, 2026-08-02
- A Mps non piace l’opas di Intesa Sanpaolo: “Premio basso e rischi antitrust” – la Repubblica, 2026-07-16
Key entities
Sources
- Opas Mps, via all’istruttoria Antitrust per Intesa Sanpaolo il nodo assicurazioni — la Repubblica — Economia
Related cases
- Luigi Lovaglio counters Intesa Sanpaolo's hostile bid for Monte dei Paschi with simultaneous offers for BPM and Generali
- Montepaschi CEO defends bank's integrity amid Premier Meloni's opposition to a potential Intesa Sanpaolo takeover
- Intesa Sanpaolo launches Call4Innovation with Ideofarm to scout deep‑tech and new‑materials startups across Europe
- Italian industrial districts, source of most of the country’s manufacturing trade surplus, are looking to Mercosur to counter tariff and Gulf pressures
- Monte dei Paschi’s CEO says the board is evaluating Banco BPM’s proposal and Intesa Sanpaolo’s offer while observing the passivity rule
- Auto insurance premiums rise as Ivass signals antitrust reform